Gd-BOPTA - General Information:
In magnetic resonance imaging (MRI), visualization of normal and pathological brain tissue depends in part on variations in the radiofrequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in the T2. When placed in a magnetic field, Gd-BOPTA shortens both the T1 and the T2 relaxation times in tissues where it accumulates. At clinical doses, Gd-BOPTA primarily affects the T1 relaxation time, thus producing an increase in signal intensity. Gd-BOPTA does not cross the intact blood-brain barrier; therefore, it does not accumulate in normal brain tissue or in central nervous system (CNS) lesions that have not caused an abnormal blood-brain barrier (e.g., cysts, mature post-operative scars).
Gadobenate dimeglumine shares the pharmacokinetic properties of the ECF contrast agent gadopentetate dimeglumine; however, gadobenate differs in that is also selectively taken-up by hepatocytes and excreted via the bile (up to 5% of dose). The elimination half-life of gadobenate dimeglumine is approximately 1 hour. It is not metabolized.
Other Brand Names containing Gadobenate Dimeglumine:
Indication, Mechanism Of Action, Drug Interactions, Food Interactions, etc..